NDAINJECTIONINJECTABLE
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIMARK (gadoversetamide) is a gadolinium-based contrast agent administered via injection for diagnostic MRI imaging. It enhances visualization of lesions in the brain, spine, and body tissues by altering magnetic properties in targeted areas. The drug belongs to the contrast media class and is used to improve diagnostic accuracy in magnetic resonance imaging procedures.
LOE Approaching
As LOE approaches, the brand team is likely contracting; focus shifts from growth initiatives to lifecycle management and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Started Feb 2009
0Nephrogenic Systemic FibrosisRenal Insufficiency
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Started May 2002
100 enrolled
Pathological Processes
Career Relevance
Working on OPTIMARK during its LOE phase offers experience in defensive brand management, pricing strategy, and channel optimization rather than growth-stage innovation. This role builds expertise in protecting market share and managing product transitions in mature therapeutic categories.
Worked on OPTIMARK at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.